Sabrina Malone Jenkins

Dr. Sabrina Malone Jenkins


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2022 in Cold Spring Harbor Molecular Case Studies
Verified
Journal Article
Open access
PDF file
HRHayley M. Reynolds
Hayley M. Reynolds
TWTing Wen
Ting Wen
AFAndrew Farrell
Andrew Farrell
RMRong Mao
Rong Mao
BMBarry Moore
Barry Moore
SJSabrina Malone Jenkins
Sabrina Malone Jenkins
Congenital myasthenic syndrome (CMS) is a group of 32 disorders involving genetic dysfunction at the neuromuscular junction resulting in skeletal muscle weakness that worsens with physical activity. Precise diagnosis and molecular subtype identification are critical for treatment as medication for one subtype may exacerbate disease in another (Engel et al.,Lancet Neurol14: 420 [2015]; Finsterer,Orphanet J Rare Dis14: 57 [2019]; Prior and Ghosh,J Child Neurol36: 610 [2021]). TheSNAP25-related CMS subtype (congenital myasthenic syndrome 18, CMS18; MIM #616330) is a rare disorder characterized by muscle fatigability, delayed psychomotor development, and ataxia. Herein, we performed rapid whole-genome sequencing (rWGS) on a critically ill newborn leading to the discovery of an unreported pathogenic de novoSNAP25c.529C > T; p.Gln177Ter variant. In this report, we present a novel case of CMS18 with complex neonatal consequence. This discovery offers unique insight into the extent of phenotypic severity in CMS18, expands the reportedSNAP25variant phenotype, and paves a foundation for personalized management for CMS18.

16 January 2025 in Pediatric Research
Verified
Journal Article
Closed access
PDF file
SJSabrina Malone Jenkins
Sabrina Malone Jenkins
RPRachel Palmquist
Rachel Palmquist
BSBrian J. Shayota
Brian J. Shayota
CSChelsea M. Solorzano
Chelsea M. Solorzano
JBJoshua L. Bonkowsky
Joshua L. Bonkowsky
MTMartin Tristani-Firouzi
Martin Tristani-Firouzi

1 October 2021 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
SJSabrina Malone Jenkins
Sabrina Malone Jenkins
GCGary Chan
Gary Chan
KWKimberlee Weaver-Lewis
Kimberlee Weaver-Lewis
TBTyler Bardsley
Tyler Bardsley
JFJace Felix
Jace Felix
MGMatthew Grinsell
Matthew Grinsell

4 February 2022 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
TNThomas J. Nicholas
Thomas J. Nicholas
NANajla Al‐Sweel
Najla Al‐Sweel
AFAndrew Farrell
Andrew Farrell
RMRong Mao
Rong Mao
PBPinar Bayrak‐Toydemir
Pinar Bayrak‐Toydemir
SJSabrina Malone Jenkins
Sabrina Malone Jenkins
Background: Genetic disorders contribute to significant morbidity and mortality in critically ill newborns. Despite advances in genome sequencing technologies, a majority of neonatal cases remain unsolved. Complex structural variants (SVs) often elude conventional genome sequencing variant calling pipelines and will explain a portion of these unsolved cases.Methods: As part of the Utah NeoSeq project, we used a research‐based, rapid whole‐genome sequencing (WGS) protocol to investigate the genomic etiology for a newborn with a left‐sided congenital diaphragmatic hernia (CDH) and cardiac malformations, whose mother also had a history of CDH and atrial septal defect.Results: Using both a novel, alignment‐free and traditional alignment‐based variant callers, we identified a maternally inherited complex SV on chromosome 8, consisting of an inversion flanked by deletions. This complex inversion, further confirmed using orthogonal molecular techniques, disrupts the ZFPM2 gene, which is associated with both CDH and various congenital heart defects.Conclusions: Our results demonstrate that complex structural events, which often are unidentifiable or not reported by clinically validated testing procedures, can be discovered and accurately characterized with conventional, short‐read sequencing and underscore the utility of WGS as a first‐line diagnostic tool.

1 June 2023 in Children
Verified
Journal Article
Open access
PDF file
JRJoseph Reiley
Joseph Reiley
PBPablo Botas
Pablo Botas
CMChristine E. Miller
Christine E. Miller
JZJian Zhao
Jian Zhao
SJSabrina Malone Jenkins
Sabrina Malone Jenkins
LBLuca Brunelli
Luca Brunelli
Mendelian disorders are prevalent in neonatal and pediatric intensive care units and are a leading cause of morbidity and mortality in these settings. Current diagnostic pipelines that integrate phenotypic and genotypic data are expert-dependent and time-intensive. Artificial intelligence (AI) tools may help address these challenges. Dx29 is an open-source AI tool designed for use by clinicians. It analyzes the patient’s phenotype and genotype to generate a ranked differential diagnosis. We used Dx29 to retrospectively analyze 25 acutely ill infants who had been diagnosed with a Mendelian disorder, using a targeted panel of ~5000 genes. For each case, a trio (proband and both parents) file containing gene variant information was analyzed, alongside patient phenotype, which was provided to Dx29 by three approaches: (1) AI extraction from medical records, (2) AI extraction with manual review/editing, and (3) manual entry. We then identified the rank of the correct diagnosis in Dx29’s differential diagnosis. With these three approaches, Dx29 ranked the correct diagnosis in the top 10 in 92–96% of cases. These results suggest that non-expert use of Dx29’s automated phenotyping and subsequent data analysis may compare favorably to standard workflows utilized by bioinformatics experts to analyze genomic data and diagnose Mendelian diseases.

9 August 2021 in Journal of Clinical and Translational Science
Verified
Journal Article
Open access
PDF file
SJSabrina Malone Jenkins
Sabrina Malone Jenkins
RPRachel Palmquist
Rachel Palmquist
AKAshley L. Kapron
Ashley L. Kapron
CTCarrie Torr
Carrie Torr
DBD. Hunter Best
D. Hunter Best
JBJoshua L. Bonkowsky
Joshua L. Bonkowsky
Rapid whole genome sequencing (rapid WGS) is a powerful diagnostic tool that is becoming increasingly practical for widespread clinical use. However, protocols for its use are challenging to implement. A significant obstacle to clinical adoption is that laboratory certification requires an initial research development phase, which is constrained by regulations from returning results. Regulations preventing return of results have ethical implications in cases which might impact patient outcomes. Here, we describe our experience with the development of a rapid WGS research protocol, that balanced the requirements for laboratory-validated test development with the ethical needs of clinically relevant return of results.